Leflunomide
- Generic Name
- Leflunomide
- Brand Names
- Arava, Leflunomide medac, Leflunomide Zentiva (previously Leflunomide Winthrop), Leflunomide ratiopharm
- Drug Type
- Small Molecule
- Chemical Formula
- C12H9F3N2O2
- CAS Number
- 75706-12-6
- Unique Ingredient Identifier
- G162GK9U4W
- Background
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
- Indication
For the management of the signs and symptoms of active rheumatoid arthritis (RA) to improve physical function and to slow the progression of structural damage associated with the disease. Has also been used for the prevention of acute and chronic rejection in recipients of solid organ trasnplants and is designated by the FDA as an orphan drug for this use.
- Associated Conditions
- Juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis
The Registry Study of Takayasu Arteritis in East China
- Conditions
- Takayasu ArteritisTreatment RefusalOutcomeMechanisms, DefensePregnancy Related
- Interventions
- Biological: Tocilizumab
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT03893136
- Locations
- 🇨🇳
Department of Rheumatology in Zhongshan hospital, Fudan University, Shanghai, Shanghai, China
Psoriatic Oligoarthritis Intervention With Symptomatic thErapy
- Conditions
- Psoriatic Arthritis
- Interventions
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 1
- Registration Number
- NCT03797872
- Locations
- 🇬🇧
Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
- Conditions
- Psoriatic Arthritis
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 206
- Registration Number
- NCT03739853
- Locations
- 🇬🇧
Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
- Conditions
- Breast NeoplasmsBreast DiseasesMetastatic Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Joseph Sparano
- Target Recruit Count
- 54
- Registration Number
- NCT03709446
- Locations
- 🇺🇸
Mt Sinai Chelesa, New York, New York, United States
🇺🇸Mt Sinai West, New York, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- P. Verschueren
- Target Recruit Count
- 284
- Registration Number
- NCT03649061
- Locations
- 🇧🇪
UZ Leuven, Leuven, Vlaams Brabant, Belgium
🇧🇪CHU Liège, Liège, Belgium
🇧🇪CHU Saint Pierre, Brussel, Belgium
Treatment With Leflunomide in Patients With Polymyalgia Rheumatica
- First Posted Date
- 2018-07-03
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Elisabeth Brouwer
- Target Recruit Count
- 94
- Registration Number
- NCT03576794
- Locations
- 🇳🇱
ZGT Almelo, Almelo, Netherlands
🇳🇱University Medical Center Groningen, Groningen, Netherlands
Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT03449758
- Locations
- 🇫🇷
Investigational Site Number 250014, Caen, France
🇫🇷Investigational Site Number 250006, Besancon, France
🇫🇷Investigational Site Number 250016, Bordeaux, France
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 400
- Registration Number
- NCT03414502
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Jawaharlal Institute of Postgraduate Medical Education & Research
- Target Recruit Count
- 136
- Registration Number
- NCT02930343
- Locations
- 🇮🇳
Department of Clinical Immunology , Jawaharlal Institute of Post graduate Medical Educationa and Research, Pondicherry, India
Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World"
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: methotrexate(necessary)Biological: etanerceptBiological: infliximabBiological: adalimumabDrug: NSAIDs (permitted,not necessary)Drug: Glucocorticoids (permitted,not necessary)
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Fen Li
- Target Recruit Count
- 240
- Registration Number
- NCT02878161
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.